QPPV.COM KNOWLEDGE ASSESSMENT

Tafamidis: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tafamidis: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the ATTR-ACT population and its relationship to the neuropathy programme?
Question 2 of 10 A patient taking tafamidis has a low total thyroxine result but no thyroid symptoms. Which follow-up best supports an accurate safety assessment?
Question 3 of 10 A patient's records contain no family history of ATTR, and genetic testing has not been documented. Which classification is most appropriate?
Question 4 of 10 A medication reconciliation lists tafamidis meglumine 20 mg capsules and tafamidis 61 mg capsules. Which conclusion is most appropriate?
Question 5 of 10 For an EU case involving a patient with hereditary ATTR cardiomyopathy, how should the 61 mg Vyndaqel film-coated tablet's indication be interpreted?
Question 6 of 10 Why should long-term extension findings not be treated as a second placebo-controlled randomised trial?
Question 7 of 10 A US case report describes tafamidis prescribed for ATTR polyneuropathy. Which regulatory point should the assessor bear in mind?
Question 8 of 10 A patient has systemic amyloidosis, but the precursor protein has not been established. Which interpretation is most appropriate before attributing potential benefit to tafamidis?
Question 9 of 10 A reviewer is assessing an EU Tafamidis Accord report and needs to determine whether the use was authorised. Which approach is most appropriate?
Question 10 of 10 Why did ATTR-ACT use a hierarchical comparison that prioritised all-cause mortality over cardiovascular hospitalisation?

Select an answer to continue.

QPPV.com